SCP
SVA

Seizert Capital Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

Seizert Capital Partners’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,062
Closed -$275K – 232
2018
Q3 		$275K Buy
+36,062
New +$260K 0.01% 197

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Seizert Capital Partners's SVA Position: Q4 2018 in Review

Seizert Capital Partners sold out of Sinovac Biotech, Ltd (SVA) in Q4 2018, closing a stake of 36,062 shares — an estimated $275K sold.

Seizert Capital Partners first reported a position in SVA in Q3 2018 and held it in 1 quarter. The position peaked at $275K in Q3 2018. 27 funds tracked by Wall St. Rank hold SVA as of Q4 2018.

  • Seizert Capital Partners reported no remaining Sinovac Biotech, Ltd position as of Q4 2018 after selling out during the quarter.
  • Seizert Capital Partners sold 36,062 Sinovac Biotech, Ltd shares in Q4 2018, an estimated $275K.
  • Seizert Capital Partners first reported a position in Sinovac Biotech, Ltd in Q3 2018 and held it in 1 quarter.
  • Seizert Capital Partners's Sinovac Biotech, Ltd position peaked at $275K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2018.

Based on Seizert Capital Partners's 13F filing for Q4 2018, filed 8 Feb 2019.